HIV Pre-Exposure Prophylaxis (PrEP) Risk Assessment Tool:
Population Cost-Effectiveness Calculator

1. Special populations: Evaluation of monogamous, serodiscordant relationships? Yes No
2. HIV prevalence in this population: (click here for CDC estimates of HIV prevalence among MSM by metropolitan area, age, and race/ethnicity. If left blank, the national average of 19% will be used) %
3. Prevalence of antiretroviral therapy use among HIV positive persons in this population: (if left blank, the CDC estimated national average of 36% will be used) %
4. Prevalence of condom use in this population: (if left blank, the literature estimate of 40% will be used) %


Switch to Individual Risk Calculator

This tool uses a decision analysis model of HIV transmission to estimate the cost-effectiveness of oral Pre-Exposure Prophylaxis (PrEP) with daily emtricitabine-tenofovir in different populations of men who have sex with men (MSM). Click here to download model calculations for review.